|
|
Maxim Biotech, Inc.Profile date: 2025-01-07 Maxim Biomedical, Inc. (MaximBio)
Overview and Core Mission
Maxim Biomedical, Inc., operating commercially as MaximBio, is an American in vitro diagnostics (IVD) company headquartered in Rockville, Maryland. For over two decades, MaximBio has specialized in the end-to-end development, contract manufacturing, and commercialization of rapid diagnostic tests and life science technologies. Operating out of an FDA-registered and ISO 13485:2016-certified facility, the organization serves commercial diagnostic partners, retail channels, clinical healthcare providers, and federal government agencies.
The entity operates both as an independent provider of branded over-the-counter (OTC) and point-of-care (POC) diagnostic kits and as a full-service Contract Development and Manufacturing Organization (CDMO) for third-party healthcare companies.
Continue…
Primary Products and In Vitro Diagnostics
MaximBio designs and manufactures diagnostic platforms focused on infectious diseases, women's health, and acute health monitoring. Their key product offerings include:
1. ClearDetect COVID-19 Antigen Home Test
- Technology: Lateral flow immunoassay utilizing visual or fluorescent detection of nucleocapsid protein antigens from SARS-CoV-2.
- Format: Over-the-counter (OTC), non-prescription self-test utilizing anterior nasal (nares) swab samples.
- Execution: Provides results within 15 minutes without requiring specialized laboratory equipment or specialized readers.
- Government Partnerships: Developed in collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative and the U.S. Department of Defense (DoD), delivering over 22 million units for federal distribution programs.
2. Custom and Private Label Immunoassays
- Branded and OEM Solutions: Production of private-label diagnostic kits distributed through retail, clinical, and institutional healthcare channels.
- Test Formats: Immunoassay platforms built across cassette, dipstick, and microplate (ELISA) layouts.
Contract Development and Manufacturing Services (CDMO)
A major portion of MaximBio's operational focus lies in serving as an integrated CDMO for emerging diagnostic startups and Fortune 100 healthcare enterprises. Their service chain spans the entire lifecycle from early concept to high-volume commercial production.
Assay Development Services
- Antibody and Reagent Engineering: Custom antibody screening, selection, purification, and conjugate chemical synthesis (utilizing visual nanoparticles, enzymes, and fluorescent labels).
- Formulation: Custom buffer and reagent formulation optimized for stability, sensitivity, and shelf-life extension.
- Platform Adaptation: Development across multiple diagnostic disciplines, including lateral flow assays, Enzyme-Linked Immunosorbent Assays (ELISA), Polymerase Chain Reaction (PCR), and isothermal nucleic acid amplification.
- Sample Compatibilities: Engineering tests compatible with whole blood, serum, plasma, saliva, nasal/nasopharyngeal swabs, urine, and environmental samples.
- Regulatory Support: Strategic assistance for FDA pre-submissions, 510(k) clearances, Premarket Approvals (PMA), Biologics License Applications (BLA), and Emergency Use Authorizations (EUA).
Commercial Manufacturing Capabilities
- Cleanroom Infrastructure: High-capacity manufacturing conducted within ISO 5, ISO 7, and ISO 8 certified cleanroom environments, alongside specialized low-humidity dry rooms for moisture-sensitive reagents.
- Reel-to-Reel Processing: Automated reel-to-reel reagent dispensing, membrane lamination, precision web cutting, and cassette assembly.
- Microplate Processing: Specialized automated equipment for microplate coating, blocking, and liquid drying for ELISA platforms.
- Aseptic Dispensing and Packaging: High-speed liquid buffer formulation, automated vial filling, tube sealing, multi-component kit assembly, and protective packaging.
- Quality Assurance and Control: Comprehensive in-process testing, lot release testing, and regulatory documentation control compliant with FDA Class I, II, and III (BLA-regulated) medical device standards.
- Fulfillment and Logistics: Climate-controlled warehousing, cold-chain storage management, and direct distribution logistics.
Operational Infrastructure and Technical Strengths
MaximBio differentiates itself through an integrated, single-site development and production model located in Rockville, Maryland. This infrastructure provides continuity during technical transfers, ensuring that assays designed in the laboratory transition directly to automated production lines without external supply chain handoffs.
- Facilities: FDA-registered medical device facility featuring specialized biochemistry, molecular biology, and assembly environments.
- Quality Standards: ISO 13485:2016 certification for medical device quality management systems, paired with FDA BLA-compliant infrastructure capable of handling highly regulated Class III IVD products.
- Scalability: Automated manufacturing equipment engineered to ramp output from pilot-scale validation runs to tens of millions of diagnostic units per month during public health emergencies or global commercial rollouts.
|
|
